Healthpeak Properties, Inc. (NYSE: DOC), a leading owner,
operator, and developer of real estate for healthcare discovery and
delivery, today announced results for the first quarter ended March
31, 2024.
FIRST QUARTER 2024 FINANCIAL PERFORMANCE AND RECENT
HIGHLIGHTS
– Net income of $0.01 per share, Nareit FFO of $0.27 per share,
FFO as Adjusted of $0.45 per share, AFFO of $0.41 per share, and
Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of
4.5%
– First quarter new and renewal lease executions totaled 1.6
million square feet:
- Outpatient Medical new and renewal lease executions totaled 1.4
million square feet
- Lab new and renewal lease executions totaled 155,000 square
feet
- Signed letters of intent on an additional 455,000 square feet
of lab leases
– Increased full year 2024 diluted earnings guidance to a range
of $0.16 – $0.20 per share; increased the midpoint of 2024 FFO as
Adjusted and AFFO guidance by +$0.02 per share, respectively and
increased Total Merger-Combined Same-Store Cash (Adjusted) NOI
growth guidance by 25 basis points at the midpoint
- Year one merger-related synergy forecast increased by $5
million to $45 million
- Repurchased $100 million of common stock at an average price of
$17.11 per share
– Year-to-date, completed property management internalization in
10 markets covering 17 million square feet
– Year-to-date dispositions and seller financing repayments
total $363 million and $69 million, respectively
– As previously announced, entered into a new $750 million term
loan and related swaps to fix the interest rate at 4.5% for the
full five-year term of the loan
– Net Debt to Adjusted EBITDAre was 5.2x for the quarter ended
March 31, 2024
– Recent sustainability and corporate impact achievements
include:
- Earned the 2024 ENERGY STAR® Partner of the Year Award for
Sustained Excellence from the U.S. Environmental Protection Agency
and the U.S. Department of Energy, marking Healthpeak's fourth time
being named Partner of the Year and first time being recognized for
Sustained Excellence
- Named a 2024 Green Lease Leader (Gold) by the Institute for
Market Transformation for the first time
- Reaffirmed our commitment to advance intentional equity,
diversity, and inclusion efforts by renewing our CEO Action for
Diversity & Inclusion™ pledge
To learn more about Healthpeak's commitment to responsible
business, please visit www.healthpeak.com/ESG.
FIRST QUARTER COMPARISON
Three Months Ended March 31,
2024
Three Months Ended March 31,
2023
(in thousands, except per share
amounts)
Amount
Per Share
Amount
Per Share
Net income, diluted
$
6,477
$
0.01
$
117,698
$
0.22
Nareit FFO, diluted
162,206
0.27
230,443
0.42
FFO as Adjusted, diluted
277,480
0.45
231,881
0.42
AFFO, diluted
247,757
0.41
209,299
0.38
Nareit FFO, FFO as Adjusted, AFFO, Total Merger-Combined
Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre
are supplemental non-GAAP financial measures that we believe are
useful in evaluating the operating performance and financial
position of real estate investment trusts (see the "Funds From
Operations" and "Adjusted Funds From Operations" sections of this
release for additional information). See "March 31, 2024 Discussion
and Reconciliation of Non-GAAP Financial Measures" for definitions,
discussions of their uses and inherent limitations, and
reconciliations to the most directly comparable financial measures
calculated and presented in accordance with GAAP in the Investor
Relations section of our website at
http://ir.healthpeak.com/quarterly-results.
MERGER-COMBINED SAME-STORE ("SS") OPERATING SUMMARY
Year-Over-Year Total Merger-Combined SS
Cash (Adjusted) NOI Growth
Three Month
SS Growth %
% of SS
Outpatient Medical
2.6%
56.3%
Lab
2.7%
34.4%
CCRC
26.6%
9.3%
Total Merger-Combined SS Cash
(Adjusted) NOI
4.5%
100.0%
PHYSICIANS REALTY TRUST MERGER INTEGRATION
As previously disclosed, on March 1, 2024, Healthpeak closed the
merger with Physicians Realty Trust.
To date, the company has completed internalization of property
management in 10 markets covering 17 million square feet.
Healthpeak now forecasts year one merger-related synergies of $45
million, an increase of $5 million compared to the prior
estimate.
REDEVELOPMENT UPDATE
PORTSIDE AT OYSTER POINT
During the first quarter, Healthpeak placed approximately
325,000 square feet across three buildings at its Portside at
Oyster Point ("Portside") campus in South San Francisco into
redevelopment.
Elements of the redevelopment include the addition of a fitness
center, boardroom, and outdoor meeting and gathering spaces
complemented by updated landscaping throughout the campus.
Additionally, the redevelopment will improve connectivity between
Healthpeak's Cove and Portside campuses, creating an approximately
2 million square foot amenity-rich contiguous campus at the
entrance to South San Francisco's life science market.
The enhanced amenity offering, improved connectivity, and
significantly lower tenant operating costs relative to new
construction, provide Healthpeak a competitive leasing advantage.
To date, Healthpeak has re-leased approximately 175,000 square feet
across the 465,000 square foot in active redevelopment on the
Portside campus with initial occupancy expected to commence in
mid-2024.
DISPOSITIONS AND LOAN REPAYMENTS
- Callan Ridge Joint Venture: As previously announced, in
January 2024, Healthpeak sold a 65% interest in the fully leased
Callan Ridge lab campus in the Torrey Pines submarket of San Diego.
The formation of the joint venture valued Callan Ridge at $236
million, or $1,275 per square foot, and represents a stabilized
cash capitalization rate of 5.3% based on the initial annual rental
rate of approximately $67 per square foot. At closing, net proceeds
to Healthpeak were $128 million. Additionally, the formation of the
joint venture reduces Healthpeak's future tenant improvement
funding by approximately $20 million.
- Outpatient Medical Dispositions: In March 2024,
Healthpeak sold two outpatient medical buildings for $29
million.
- Poway R&D Portfolio: In April 2024, Healthpeak sold
a portfolio of seven buildings in the Poway submarket of San Diego
for $180 million. The portfolio comprises R&D, industrial, and
office spaces across 702,000 square feet and is fully-leased to an
affiliate of General Atomics. The trailing cash capitalization rate
on the disposition was 6.0%.
- Loan Repayments: During the first quarter, we received
$69 million of seller financing loan repayments.
SHARE REPURCHASE ACTIVITY
In March 2024, Healthpeak repurchased 5.8 million shares at a
weighted average share price of $17.11 for approximately $100
million under its $500 million share repurchase program. As of
March 31, 2024, $344 million remained available for share
repurchases under the program.
CAPITAL MARKETS
As previously announced, Healthpeak entered into a new $750
million 5-year unsecured term loan on March 1, 2024. Healthpeak
entered into swap agreements to fix the interest rate of the new
term loan at approximately 4.5% for the full 5-year term of the
loan.
As of April 25, 2024, Healthpeak had $3.1 billion in available
liquidity through a combination of unrestricted cash and full
capacity of its $3 billion revolving credit facility.
BOARD OF DIRECTORS
On April 25, 2024, Christine N. Garvey and David B. Henry
retired from Healthpeak's Board pursuant to the director term limit
policy. Healthpeak's Board of Directors reduced the size of the
Board to 11 members.
DIVIDEND
On April 24, 2024, Healthpeak's Board declared a quarterly
common stock cash dividend of $0.30 per share to be paid on May 17,
2024, to stockholders of record as of the close of business on May
6, 2024.
2024 GUIDANCE
We are updating the following guidance ranges for full year
2024:
- Diluted earnings per common share from $0.07 – $0.13 to $0.16 –
$0.20
- Diluted Nareit FFO per share from $1.54 – $1.60 to $1.56 –
$1.60
- Diluted FFO as Adjusted per share from $1.73 – $1.79 to $1.76 –
$1.80
- Diluted AFFO per share from $1.50 – $1.56 to $1.53 – $1.57
- Total Merger-Combined Same-Store Cash (Adjusted) NOI growth
from 2.25% – 3.75% to 2.50% – 4.00%
These estimates are based on our view of existing market
conditions, transaction timing, and other assumptions for the year
ending December 31, 2024. For additional details and assumptions,
please see page 12 in our corresponding Supplemental Report and the
Discussion and Reconciliation of Non-GAAP Financial Measures, both
of which are available in the Investor Relations section of our
website at http://ir.healthpeak.com.
CONFERENCE CALL INFORMATION
Healthpeak has scheduled a conference call and webcast for
Friday, April 26, 2024, at 7:00 a.m. Mountain Time.
The conference call can be accessed in the following ways:
- Healthpeak’s website:
https://ir.healthpeak.com/news-events
- Webcast: https://events.q4inc.com/attendee/344417431. Joining
via webcast is recommended for those who will not be asking
questions.
- Telephone: The participant dial-in number is (800)
715-9871.
An archive of the webcast will be available on Healthpeak’s
website through April 25, 2025, and a telephonic replay can be
accessed through May 3, 2024, by dialing (800) 770-2030 and
entering conference ID number 95156.
ABOUT HEALTHPEAK
Healthpeak Properties, Inc. is a fully integrated real estate
investment trust (REIT) and S&P 500 company. Healthpeak owns,
operates and develops high-quality real estate for healthcare
discovery and delivery.
FORWARD-LOOKING STATEMENTS
Statements contained in this release that are not historical
facts are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements include, among other things, statements
regarding our and our officers' intent, belief or expectation as
identified by the use of words such as "may," "will," "project,"
"expect," "believe," "intend," "anticipate," "seek," "target,"
"forecast," "plan," "potential," "estimate," "could," "would,"
"should" and other comparable and derivative terms or the negatives
thereof. Examples of forward-looking statements include, among
other things: (i) statements regarding timing, outcomes and other
details relating to current, pending or contemplated acquisitions,
dispositions, transitions, developments, redevelopments, joint
venture transactions, leasing activity and commitments, financing
activities, or other transactions discussed in this release,
including statements regarding our anticipated synergies from our
merger with Physicians Realty Trust; (ii) the payment of a
quarterly cash dividend; and (iii) the information presented under
the heading "2024 Guidance." Pending acquisitions, dispositions,
joint venture transactions, leasing activity, and financing
activity, including those subject to binding agreements, remain
subject to closing conditions and may not be completed within the
anticipated timeframes or at all. Forward-looking statements
reflect our current expectations and views about future events and
are subject to risks and uncertainties that could significantly
affect our future financial condition and results of operations.
While forward-looking statements reflect our good faith belief and
assumptions we believe to be reasonable based upon current
information, we can give no assurance that our expectations or
forecasts will be attained. Further, we cannot guarantee the
accuracy of any such forward-looking statement contained in this
release, and such forward-looking statements are subject to known
and unknown risks and uncertainties that are difficult to predict.
These risks and uncertainties include, but are not limited to:
macroeconomic trends, including inflation, interest rates,
construction and labor costs, and unemployment; risks associated
with our merger with Physicians Realty Trust (the “Merger”),
including, but not limited to, our ability to integrate the
operations of the Company and Physicians Realty Trust successfully
and realize the anticipated synergies and other benefits of the
Merger or do so within the anticipated time frame; changes within
the industries in which we operate; significant regulation, funding
requirements, and uncertainty faced by our lab tenants; factors
adversely affecting our tenants’, operators’, or borrowers’ ability
to meet their financial and other contractual obligations to us;
the insolvency or bankruptcy of one or more of our major tenants,
operators, or borrowers; our concentration of real estate
investments in the healthcare property sector, which makes us more
vulnerable to a downturn in that specific sector than if we
invested across multiple sectors; the illiquidity of real estate
investments; our ability to identify and secure new or replacement
tenants and operators; our property development, redevelopment, and
tenant improvement risks, including project abandonments, project
delays, and lower profits than expected; the ability of the
hospitals on whose campuses our outpatient medical buildings are
located and their affiliated healthcare systems to remain
competitive or financially viable; our ability to develop,
maintain, or expand hospital and health system client
relationships; operational risks associated with third-party
management contracts, including the additional regulation and
liabilities of our properties operated through structures permitted
by the Housing and Economic Recovery Act of 2008, which includes
most of the provisions previously proposed in the REIT Investment
Diversification and Empowerment Act of 2007 (commonly referred to
as “RIDEA”); economic conditions, natural disasters, weather, and
other conditions that negatively affect geographic areas where we
have concentrated investments; uninsured or underinsured losses,
which could result in significant losses and/or performance
declines by us or our tenants and operators; our use of joint
ventures that may limit our returns on and our flexibility with
jointly owned investments; our use of fixed rent escalators,
contingent rent provisions, and/or rent escalators based on the
Consumer Price Index; competition for suitable healthcare
properties to grow our investment portfolio; our ability to
foreclose or exercise rights on collateral securing our real
estate-related loans; any requirement that we recognize reserves,
allowances, credit losses, or impairment charges; investment of
substantial resources and time in transactions that are not
consummated; our ability to successfully integrate or operate
acquisitions; the potential impact on us and our tenants,
operators, and borrowers from litigation matters, including rising
liability and insurance costs; environmental compliance costs and
liabilities associated with our real estate investments; our
ability to satisfy environmental, social and governance and
sustainability commitments and requirements, as well as stakeholder
expectations; epidemics, pandemics, or other infectious diseases,
including the coronavirus disease (Covid), and health and safety
measures intended to reduce their spread; human capital risks,
including the loss or limited availability of our key personnel;
our reliance on information technology systems and any material
failure, inadequacy, interruption, or security failure of that
technology; volatility, disruption, or uncertainty in the financial
markets; increased borrowing costs, including due to rising
interest rates; cash available for distribution to stockholders and
our ability to make dividend distributions at expected levels; the
availability of external capital on acceptable terms or at all,
including due to rising interest rates, changes in our credit
ratings and the value of our common stock, bank failures or other
events affecting financial institutions and other factors; our
ability to manage our indebtedness level and covenants in and
changes to the terms of such indebtedness; the failure of our
tenants, operators, and borrowers to comply with federal, state,
and local laws and regulations, including resident health and
safety requirements, as well as licensure, certification, and
inspection requirements; required regulatory approvals to transfer
our senior housing properties; compliance with the Americans with
Disabilities Act and fire, safety, and other regulations; laws or
regulations prohibiting eviction of our tenants; the requirements
of, or changes to, governmental reimbursement programs such as
Medicare or Medicaid; legislation to address federal government
operations and administrative decisions affecting the Centers for
Medicare and Medicaid Services; our participation in the
Coronavirus, Aid, Relief and Economic Security Act Provider Relief
Fund and other Covid-related stimulus and relief programs; our
ability to maintain our qualification as a real estate investment
trust (“REIT”); our taxable REIT subsidiaries being subject to
corporate level tax; tax imposed on any net income from “prohibited
transactions”; changes to U.S. federal income tax laws, and
potential deferred and contingent tax liabilities from corporate
acquisitions; calculating non-REIT tax earnings and profits
distributions; ownership limits in our charter that restrict
ownership in our stock; provisions of Maryland law and our charter
that could prevent a transaction that may otherwise be in the
interest of our stockholders; conflicts of interest between the
interests of our stockholders and the interests of holders of
Healthpeak OP, LLC (“Healthpeak OP”) common units; provisions in
the operating agreement of Healthpeak OP and other agreements that
may delay or prevent unsolicited acquisitions and other
transactions; our status as a holding company of Healthpeak OP; and
other risks and uncertainties described from time to time in our
Securities and Exchange Commission filings.
Moreover, other risks and uncertainties of which we are not
currently aware may also affect our forward-looking statements, and
may cause actual results and the timing of events to differ
materially from those anticipated. The forward-looking statements
made in this communication are made only as of the date hereof or
as of the dates indicated in the forward-looking statements, even
if they are subsequently made available by us on our website or
otherwise. We do not undertake any obligation to update or
supplement any forward-looking statements to reflect actual
results, new information, future events, changes in its
expectations or other circumstances that exist after the date as of
which the forward-looking statements were made.
Healthpeak Properties,
Inc.
Consolidated Balance
Sheets
In thousands, except share and
per share data
March 31, 2024
December 31, 2023
Assets
Real estate:
Buildings and improvements
$
16,571,761
$
13,329,464
Development costs and construction in
progress
735,176
643,217
Land and improvements
3,079,225
2,647,633
Accumulated depreciation and
amortization
(3,723,173
)
(3,591,951
)
Net real estate
16,662,989
13,028,363
Loans receivable, net of reserves of
$9,334 and $2,830
267,798
218,450
Investments in and advances to
unconsolidated joint ventures
930,559
782,853
Accounts receivable, net of allowance of
$2,800 and $2,282
68,567
55,820
Cash and cash equivalents
101,763
117,635
Restricted cash
55,395
51,388
Intangible assets, net
1,160,446
314,156
Assets held for sale, net
—
117,986
Right-of-use asset, net
434,010
240,155
Other assets, net
860,513
772,044
Total assets
$
20,542,040
$
15,698,850
Liabilities and Equity
Bank line of credit and commercial
paper
$
183,000
$
720,000
Term loans
1,645,180
496,824
Senior unsecured notes
6,545,209
5,403,378
Mortgage debt
382,406
256,097
Intangible liabilities, net
238,760
127,380
Liabilities related to assets held for
sale, net
—
729
Lease liability
307,119
206,743
Accounts payable, accrued liabilities, and
other liabilities
717,191
657,196
Deferred revenue
923,676
905,633
Total liabilities
10,942,541
8,773,980
Commitments and contingencies
Redeemable noncontrolling interests
54,848
48,828
Common stock, $1.00 par value:
1,500,000,000 and 750,000,000 shares authorized; 703,733,446 and
547,156,311 shares issued and outstanding
703,733
547,156
Additional paid-in capital
12,918,936
10,405,780
Cumulative dividends in excess of
earnings
(4,779,599
)
(4,621,861
)
Accumulated other comprehensive income
(loss)
38,543
19,371
Total stockholders’ equity
8,881,613
6,350,446
Joint venture partners
328,430
310,998
Non-managing member unitholders
334,608
214,598
Total noncontrolling interests
663,038
525,596
Total equity
9,544,651
6,876,042
Total liabilities and equity
$
20,542,040
$
15,698,850
Healthpeak Properties,
Inc.
Consolidated Statements of
Operations
In thousands, except per share
data
Three Months Ended March 31,
2024
2023
Revenues:
Rental and related revenues
$
462,033
$
392,431
Resident fees and services
138,776
127,084
Interest income and other
5,751
6,163
Total revenues
606,560
525,678
Costs and expenses:
Interest expense
60,907
47,963
Depreciation and amortization
219,219
179,225
Operating
243,729
223,088
General and administrative
23,299
24,547
Transaction and merger-related costs
107,220
2,425
Impairments and loan loss reserves
(recoveries), net
11,458
(2,213
)
Total costs and expenses
665,832
475,035
Other income (expense):
Gain (loss) on sales of real estate,
net
3,255
81,578
Other income (expense), net
78,516
772
Total other income (expense), net
81,771
82,350
Income (loss) before income taxes and
equity income (loss) from unconsolidated joint ventures
22,499
132,993
Income tax benefit (expense)
(13,698
)
(302
)
Equity income (loss) from unconsolidated
joint ventures
2,376
1,816
Net income (loss)
11,177
134,507
Noncontrolling interests’ share in
earnings
(4,501
)
(15,555
)
Net income (loss) attributable to
Healthpeak Properties, Inc.
6,676
118,952
Participating securities’ share in
earnings
(199
)
(1,254
)
Net income (loss) applicable to common
shares
$
6,477
$
117,698
Earnings (loss) per common
share:
Basic
$
0.01
$
0.22
Diluted
$
0.01
$
0.22
Weighted average shares
outstanding:
Basic
600,898
546,842
Diluted
601,188
547,110
Healthpeak Properties,
Inc.
Funds From Operations
In thousands, except per share
data
Three Months Ended March 31,
2024
2023
Net income (loss) applicable to common
shares
$
6,477
$
117,698
Real estate related depreciation and
amortization
219,219
179,225
Healthpeak’s share of real estate related
depreciation and amortization from unconsolidated joint
ventures
8,772
5,993
Noncontrolling interests’ share of real
estate related depreciation and amortization
(4,452
)
(4,783
)
Loss (gain) on sales of depreciable real
estate, net
(3,255
)
(81,578
)
Noncontrolling interests’ share of gain
(loss) on sales of depreciable real estate, net
—
11,546
Loss (gain) upon change of control,
net(1)
(77,781
)
—
Taxes associated with real estate
dispositions(2)
11,608
—
Nareit FFO applicable to common shares
160,588
228,101
Distributions on dilutive convertible
units and other
1,618
2,342
Diluted Nareit FFO applicable to common
shares
$
162,206
$
230,443
Diluted Nareit FFO per common
share
$
0.27
$
0.42
Weighted average shares outstanding -
Diluted Nareit FFO
608,807
554,400
Impact of adjustments to Nareit FFO:
Transaction and merger-related
items(3)
$
102,829
$
2,364
Other impairments (recoveries) and other
losses (gains), net(4)
11,853
(1,272
)
Casualty-related charges (recoveries),
net(5)
—
348
Total adjustments
114,682
1,440
FFO as Adjusted applicable to common
shares
275,270
229,541
Distributions on dilutive convertible
units and other
2,210
2,340
Diluted FFO as Adjusted applicable to
common shares
$
277,480
$
231,881
Diluted FFO as Adjusted per common
share
$
0.45
$
0.42
Weighted average shares outstanding -
Diluted FFO as Adjusted
610,632
554,400
__________________________________________
(1)
The three months ended March 31, 2024
includes a gain upon change of control related to the sale of a 65%
interest in two lab buildings in San Diego, California. The gain
upon change of control is included in other income (expense), net
in the Consolidated Statements of Operations.
(2)
The three months ended March 31, 2024
includes non-cash income tax expense related to the sale of a 65%
interest in two lab buildings in San Diego, California.
(3)
The three months ended March 31, 2024
includes costs related to the Merger, which are primarily comprised
of advisory, legal, accounting, tax, post-combination severance and
stock compensation expense, and other costs that were incurred
during the period, partially offset by $4 million of termination
fee income associated with Graphite Bio, Inc., for which the lease
terms were modified to accelerate expiration of the lease to
December 2024. Termination fee income is included in rental and
related revenues on the Consolidated Statements of Operations.
(4)
The three months ended March 31, 2024 and
2023 includes reserves and (recoveries) for expected loan losses
recognized in impairments and loan loss reserves (recoveries), net
in the Consolidated Statements of Operations.
(5)
Casualty-related charges (recoveries), net
are recognized in other income (expense), net and equity income
(loss) from unconsolidated joint ventures in the Consolidated
Statements of Operations.
Healthpeak Properties, Inc.
Adjusted Funds From
Operations
In thousands
Three Months Ended March 31,
2024
2023
FFO as Adjusted applicable to common
shares
$
275,270
$
229,541
Stock-based compensation amortization
expense
3,366
3,287
Amortization of deferred financing costs
and debt discounts (premiums)
4,522
2,821
Straight-line rents(1)
(12,093
)
(747
)
AFFO capital expenditures
(17,517
)
(22,789
)
Deferred income taxes
724
(261
)
Amortization of above (below) market lease
intangibles, net
(7,351
)
(5,803
)
Other AFFO adjustments
(1,485
)
1,610
AFFO applicable to common shares
245,436
207,659
Distributions on dilutive convertible
units and other
2,321
1,640
Diluted AFFO applicable to common
shares
$
247,757
$
209,299
Diluted AFFO per common share
$
0.41
$
0.38
Weighted average shares outstanding -
Diluted AFFO
610,632
552,575
__________________________________________
(1)
The three months ended March 31, 2023 includes an $8.7 million
write-off of straight-line rent receivable associated with Sorrento
Therapeutics, Inc., which commenced voluntary reorganization
proceedings under Chapter 11 of the U.S. Bankruptcy Code. This
activity is reflected as a reduction of rental and related revenues
in the Consolidated Statements of Operations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240425517824/en/
Andrew Johns, CFA Senior Vice President – Investor Relations
720-428-5400
Grafico Azioni Healthpeak Properties (NYSE:DOC)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Healthpeak Properties (NYSE:DOC)
Storico
Da Nov 2023 a Nov 2024